Metformin, but not Thiazolidinediones, Inhibits Plasminogen Activator Inhibitor-1 Production in Human Adipose Tissue in Vitro

Abstract

Biguanides and thiazolidinediones (TZDs), which are primarily used as anti-diabetic drugs, are also associated with other beneficial effects on cardiovascular risk factors such as reduced plasma plasminogen activator inhibitor-1 (PAI-1) concentration in both diabetic and non-diabetic obese subjects. Since human adipose tissue is of importance for the production of PAI-1, the aim of the present study was to investigate the possible direct effects of these anti-diabetic agents on PAI-1 mRNA and secretion by human adipose tissue. Adipose tissue was obtained from biopsies taken from the subcutaneous abdominal depot. Adipose tissue fragments, isolated mature adipocytes, and preadipocytes were incubated in vitro with metformin and various TZDs. Metformin (0.1 - 10 mM) dose-dependently decreased PAI-1 production (and PAI-1 mRNA) under both basal (43 % inhibition at 10 mM, p < 0.05) and interleukin-1β (IL-1β)-stimulated conditions where the levels were inhibited by 47.8 % at 1 mM metformin (p < 0.05) and by 100 % at 10 mM (p < 0.01). None of the TZDs tested (PPAR-γ agonists: troglitazone, pioglitazone, or ciglitazone) had any effects on PAI-1 production. Moreover, no effects on PAI-1 production were observed using various PPAR-α agonists such as 5, 8, 11, 14-eicosatetraynoic acid (ETYA), Wy14643 and fenofibrate. Our findings indicate no direct effects of TZDs on PAI-1 secretion, whereas metformin was able to directly inhibit PAI-1 production in human adipose tissue.

Key words

Plasminogen Activator Inhibitor-1 - Human Adipose Tissue - Metformin - Thiazolidinediones - Gene Expression - Obesity

References

• 1 Juhan-Vague I, Alessi M C. PAI-1, obesity, insulin resistance and risk of cardiovascular events.  Thromb Haemost. 1997;  78 656-660
• 2 Bastard J P, Pieroni L, Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance.  Diabetes Metab Res Rev. 2000;  16 192-201
• 3 Saltiel A R, Olefsky J M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes.  Diabetes. 1996;  45 1661-1669
• 4 Nolan J J, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.  N Engl J Med. 1994;  331 1188-1193
• 5 Kruszynska Y T, Yu J G, Olefsky J M, Sobel B E. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.  Diabetes. 2000;  49 633-639
• 6 Bailey C J. Biguanides and NIDDM.  Diabetes Care. 1992;  15 755-772
• 7 Bailey C J, Turner R C. Metformin.  N Engl J Med. 1996;  334 574-579
• 8 Matthaei S, Hamann A, Klein H H, Benecke H, Kreymann G, Flier J S, Greten H. Association of Metformin's effect to increase insulin-stimulated glucose transport with potentiation of insulin-induced translocation of glucose transporters from intracellular pool to plasma membrane in rat adipocytes.  Diabetes. 1991;  40 850-857
• 9 Abbasi F, Carantoni M, Chen Y D, Reaven G M. Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin.  Diabetes Care. 1998;  21 1301-1305
• 10 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).  Lancet. 1998;  352 854-865
• 11 Grant P J. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.  Diabetes Care. 1996;  19 64-66
• 12 Alessi M C, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor-1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease.  Diabetes. 1997;  46 860-867
• 13 Mavri A, Stegnar M, Krebs M, Sentocnik J T, Geiger M, Binder B R. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women.  Arterioscler Thromb Vasc Biol. 1999;  19 1582-1587
• 14 Gottschling-Zeller H, Rohrig K, Hauner H. Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes.  Diabetologia. 2000;  43 377-383
• 15 Anfosso F, Chomiki N, Alessi M C, Vague P, Juhan-Vague I. Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin.  J Clin Invest. 1993;  91 2185-2193
• 16 Kristensen K, Pedersen S B, Richelsen B. Regulation of leptin by steroid hormones in rat adipose tissue.  Biochem Biophys Res Commun . 1999;  259 624-630
• 17 Hauner H, Entenmann G, Wabitsch M, Gaillard D, Ailhaud G, Negrel R, Pfeiffer E F. Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium.  J Clin Invest. 1989;  84 1663-1670
• 18 Pedersen S B, Børglum J, Jørgensen J, Richelsen B. Growth hormone treatment of obese premenopausal women: effects on isolated adipocyte metabolism.  Endocrinology and Metabolism. 1995;  2 251-258
• 19 Bruun J M, Pedersen S B, Richelsen B. Interleukin-8 production in human adipose tissue. Inhibitory effects of anti-diabetic compounds, the thiazolidinedione ciglitazone, and the biguanide metformin.  Horm Metab Res . 2000;  32 537-541
• 20 Pedersen S B, Kristensen K, Fisker S, Jorgensen J O, Christiansen J S, Richelsen B. Regulation of uncoupling protein-2 and -3 by growth hormone in skeletal muscle and adipose tissue in growth hormone-deficient adults.  J Clin Endocrinol Metab. 1999;  84 4073-4078
• 21 He G, Pedersen S B, Bruun J M, Richelsen B. Regulation of plasminogen activator inhibitor-1 in human adipose tissue: interaction between cytokines, cortisol, and estrogen.  Horm Metab Res . 2000;  32 515-520
• 22 Eriksson P, Reynisdottir S, Lonnqvist F, Stemme V, Hamsten A, Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non- obese and obese individuals.  Diabetologia. 1998;  41 65-71
• 23 Kato K, Satoh H, Endo Y, Yamada D, Midorikawa S, Sato W, Mizuno K, Fujita T, Tsukamoto K, Watanabe T. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.  Biochem Biophys Res Commun . 1999;  258 431-435
• 24 Nilsson L, Takemura T, Eriksson P, Hamsten A. Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.  Arterioscler Thromb Vasc Biol. 1999;  19 1577-1581
• 25 Ihara H, Urano T, Takada A, Loskutoff D J. Induction of plasminogen activator inhibitor-1 gene expression in adipocytes by thiazolidinediones.  FASEB J. 2001;  15 1233-1235
• 26 Rieusset J, Auwerx J, Vidal H. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes.  Biochem Biophys Res Commun. 1999;  265 265-271
• 27 Bailey C J. Metformin - an update.  Gen Pharmacol. 1993;  24 1299-1309
• 28 Fischer Y, Thomas J, Rosen P, Kammermeier H. Action of metformin on glucose transport and glucose transporter GLUT1 and GLUT4 in heart muscle cells from healthy and diabetic rats.  Endocrinology. 1995;  136 412-420
• 29 Lenhard J M, Kliewer S A, Paulik M A, Plunket K D, Lehmann J M, Weiel J E. Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways.  Biochem Pharmacol. 1997;  54 801-808
• 30 Yudkin J S, Coppack S W, Bulmer K, Rawesh A, Mohamed-Ali V. Lack of evidence for secretion of plasminogen activator inhibitor-1 by human subcutaneous adipose tissue in vivo.  Thromb Res . 1999;  96 1-9
• 31 Birgel M, Gottschling-Zeller H, Rohrig K, Hauner H. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes.  Arterioscler Thromb Vasc Biol . 2000;  20 1682-1687